Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Osimertinib in Resectable EGFR-mutant NSCLC
NCT04816838Unknown
- Sponsor
- Yonsei University
- Start
- May 2021
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of osimertinib in non-small cell lung cancer (NSCLC), sponsored by Yonsei University. Primary endpoint: Objective Response Rate. Status: unknown.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04816838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04816838.